Clinical markers of early disease in persons near onset of Huntington’s disease

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Neurology

• Publication date

  2001-08-28

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1212/WNL.57.4.658PMID 11524475
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Studies of Interference in Serial Verbal Reactions

  2001cited by this paper
• Learning something ORIGINal at the Drosophila neuromuscular junction.

  1999cited by this paper
• A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration.

  1999cited by this paper
• Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology

  1999cited by this paper
• Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene.

  1998cited by this paper
• Are cognitive changes the first symptoms of Huntington’s disease? A study of gene carriers

  1998cited by this paper
• The relationship between striatal dopamine receptor binding and cognitive performance in Huntington's disease.

  1998cited by this paper
• Genetic neurodegenerative diseases: the human illness and transgenic models.

  1998cited by this paper
• Evidence for specific cognitive deficits in preclinical Huntington's disease.

  1998cited by this paper
• Genetic classification of primary neurodegenerative disease.

  1998cited by this paper
• Mutations in the TIGR gene in familial primary open-angle glaucoma in Japan.

  1997cited by this paper
• The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size.

  1997cited by this paper
• Cognitive manifestations of Huntington disease in relation to genetic structure and clinical onset.

  1997cited by this paper
• Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?

  1997cited by this paper
• Odor identification in Huntington's disease patients and asymptomatic gene carriers.

  1997cited by this paper
• Intranuclear Neuronal Inclusions : Minireview A Common Pathogenic Mechanism for Glutamine-Repeat Neurodegenerative Diseases ?

  1997cited by this paper
• Huntington disease and the related disorder, dentatorubral-pallidoluysian atrophy (DRPLA).

  1997cited by this paper
• Neuropsychological stability over two years in asymptomatic carriers of the Huntington's disease mutation.

  1996cited by this paper
• Huntington disease--another chapter rewritten.

  1996cited by this paper
• Unified Huntington's disease rating scale: reliability and consistency

  1996cited by this paper
• Motor changes in presymptomatic Huntington disease gene carriers.

  1996cited by this paper
• Huntington disease--another chapter rewritten.

  1996cited by this paper
• Striatal glucose metabolism and dopamine D2 receptor binding in asymptomatic gene carriers and patients with Huntington's disease.

  1996cited by this paper
• Basal ganglia volume and proximity to onset in presymptomatic Huntington disease.

  1996cited by this paper
• Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease

  1996cited by this paper
• Huntington's disease: translating a CAG repeat into a pathogenic mechanism

  1996cited by this paper
• Longitudinal neuropsychological and genetic linkage analysis of persons at risk for Huntington's disease.

  1995cited by this paper
• When more is less: pathogenesis of glutamine repeat neurodegenerative diseases.

  1995cited by this paper
• Neuropsychological characteristics of Huntington's disease carriers: a double blind study.

  1995cited by this paper
• Cognitive scores in carriers of huntington's disease gene compared to noncarriers

  1995cited by this paper
• Cognitive performance in UK sample of presymptomatic people carrying the gene for Huntington's disease.

  1995cited by this paper
• When more is less: pathogenesis of glutamine repeat neurodegenerative diseases.

  1995cited by this paper
• A brief assessment of frontal and subcortical functions in dementia.

  1993cited by this paper
• A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.

  1993cited by this paper
• Serial changes of cerebral glucose metabolism and caudate size in persons at risk for Huntington's disease.

  1992cited by this paper
• Evidence of presymptomatic cognitive decline in Huntington's disease.

  1992cited by this paper
• Initiation and execution of movement sequences in those suffering from and at-risk of developing Huntington's disease.

  1992cited by this paper
• Are there neuropsychologic manifestations of the gene for Huntington's disease in asymptomatic, at-risk individuals?

  1990cited by this paper
• Presymptomatic neuropsychological impairment in Huntington's disease.

  1988cited by this paper
• Reduced cerebral glucose metabolism in asymptomatic subjects at risk for Huntington's disease.

  1987cited by this paper
• Positron emission tomography in the early diagnosis of Huntington's disease

  1986cited by this paper
• Random-effects models for longitudinal data.

  1982cited by this paper
• Premorbid psychometric indicators of the gene for Huntington's disease.

  1977cited by this paper

• A deficit in semantic word learning in Huntington's Disease.

  2025cites this paper
• Auditory mismatch negativity in pre-manifest and manifest Huntington's disease.

  2024cites this paper
• Sleep fragmentation despite intact rest-activity patterns in premanifest Huntington's disease: An actigraphy study.

  2024cites this paper
• Neuropsychological performance and disease burden in individuals at risk of developing Huntington disease.

  2024cites this paper
• Prevalence of Juvenile-Onset and Pediatric Huntington’s Disease and Their Availability and Ability to Participate in Trials: A Dutch Population and Enroll-HD Observational Study

  2024cites this paper
• Sleep, Circadian Rhythms, and Cognitive Dysfunction in Huntington’s Disease

  2023cites this paper
• Advances in nanotechnology versus stem cell therapy for the theranostics of Huntington's disease

  2023cites this paper
• Malestar psicológico en portadores y no portadores de la mutación causante de enfermedad de Huntington y su relación con la carga de la enfermedad

  2022cites this paper
• Psychological discomfort in carriers and non-carriers of the Huntington disease mutation and its relationship with disease burden.

  2022cites this paper
• A novel rhesus macaque model of Huntington’s disease recapitulates key neuropathological changes along with motor and cognitive decline

  2022cites this paper
• Temporal Characterization of Behavioral and Hippocampal Dysfunction in the YAC128 Mouse Model of Huntington’s Disease

  2022cites this paper
• A novel rhesus macaque model of Huntington’s disease recapitulates key neuropathological changes along with progressive motor and cognitive decline

  2022cites this paper
• Single cell transcriptomics and epigenomics methods provide high resolution genomics profiling of brain disorders

  2021cites this paper
• Experience of joint management of patient with Huntington's chorea by neurological and dental specialists with use of tetrabenazine

  2021cites this paper
• Neuropsychological performance and disease burden in individuals at risk of developing Huntington disease.

  2021cites this paper
• The role of noradrenaline in cognition and cognitive disorders

  2021cites this paper
• Prediction of manifest Huntington disease with clinical and imaging measures: A 12-year prospective observational study

  2020cites this paper
• Identification of genetic factors underpinning phenotypic heterogeneity in Huntington's disease and other neurodegenerative disorders

  2020cites this paper
• Locus of control in patients with Huntington disease: a cross-sectional study.

  2020cites this paper
• Emotion recognition and inhibitory control in manifest and pre-manifest Huntington's disease: evidence from a new Stroop task

  2020cites this paper
• Implications of phytochemicals as disease-modifying agents against Huntington's disease (HD): Bioactivity, animal models and transgenics, synergism and structure–activity studies

  2020cites this paper
• Identification of symbol digit modality test score extremes in Huntington's disease

  2019cites this paper
• Pathology, Prevention and Therapeutics of Neurodegenerative Disease

  2019cites this paper
• Huntington disease: A quarter century of progress since the gene discovery.

  2019cites this paper
• Clinical Symptomatology of Huntington’s Disease

  2018cites this paper
• Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes

  2018cites this paper
• Understanding patient-reported outcome measures in Huntington disease: at what point is cognitive impairment related to poor measurement reliability?

  2018cites this paper
• Regional subcortical shape analysis in premanifest Huntington's disease

  2018cites this paper
• Evaluation of Cognition and Cortical Excitability in Huntington’s Disease

  2018cites this paper
• Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington’s Disease Phenotype

  2017cites this paper
• The BACHD Rat Model of Huntington Disease Shows Specific Deficits in a Test Battery of Motor Function

  2017cites this paper
• Metformin intake associates with better cognitive function in patients with Huntington's disease

  2017cites this paper
• Longitudinal diffusion changes in prodromal and early HD: Evidence of white‐matter tract deterioration

  2017cites this paper
• Disease‐modifying effects of ganglioside GM1 in Huntington's disease models

  2017cites this paper
• Cognition sociale dans la maladie de Huntington : etude cognitive et par imagerie cérébrale morphologique et fonctionnelle

  2017cites this paper
• Dementias and the Frontal Lobes

  2017cites this paper
• Striatal Neuropeptides Enhance Selection and Rejection of Sequential Actions

  2017cites this paper
• Combination of RNA Interference and Stem Cells for Treatment of Central Nervous System Diseases

  2017cites this paper
• Natural Products against Huntington's Disease (HD): Implications of Neurotoxic Animal Models and Transgenics in Preclinical Studies

  2017cites this paper
• Cognitive and behavioral changes in Huntington disease before diagnosis.

  2017cites this paper
• Neuroimaging as a tool to study the sources of phenotypic heterogeneity in Huntington's disease

  2017cites this paper
• Emotional Memory for Affective Words in Manifest and Prodromal Huntington’s Disease

  2017cites this paper
• Molecular Imaging of Huntington's Disease

  2017cites this paper
• Huntington disease: a single-gene degenerative disorder of the striatum

  2016cites this paper
• Longitudinal Changes in the Motor Learning-Related Brain Activation Response in Presymptomatic Huntington's Disease

  2016cites this paper
• Multimodality Imaging of Huntington’s Disease

  2016cites this paper
• Cognitive dysfunction in Huntington's disease: mechanisms and therapeutic strategies beyond BDNF

  2016cites this paper
• Fronto-striatal circuitry in children at risk for Huntington's disease

  2016cites this paper
• An evaluation of cognitive deficits in a rat-model of Huntington's disease

  2016influential citation
• Development of Research on Huntington Disease in China

  2016cites this paper
• A comparison of discrimination learning in touchscreen and 2-choice swim tank using an allelic series of Huntington's disease mice.

  2016cites this paper
• Cognitive deficits predict poorer functional capacity in Huntington's disease: but what is being measured?

  2015cites this paper
• Intra-individual Variability in Prodromal Huntington Disease and Its Relationship to Genetic Burden

  2015cites this paper
• A role for Kalirin-7 in corticostriatal synaptic dysfunction in Huntington's disease.

  2015cites this paper
• Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.

  2015cites this paper
• The role of iron in gray matter degeneration in Huntington's disease: A magnetic resonance imaging study

  2015influential citation
• Clinical Aspects of Huntington's Disease.

  2015cites this paper
• Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease

  2014cites this paper
• Striatal metabolism and psychomotor speed as predictors of motor onset in Huntington’s disease

  2014cites this paper
• Die Rolle von Mangan bei neurodegenerativen Erkrankungen

  2014cites this paper
• Results of the citalopram to enhance cognition in Huntington disease trial

  2014cites this paper
• Prediction of manifest Huntington's disease with clinical and imaging measures: a prospective observational study.

  2014cites this paper
• MRI measures of corpus callosum iron and myelin in early Huntington's disease

  2014influential citation
• Prospects for neuroprotective therapies in prodromal Huntington's disease

  2014cites this paper
• The cognitive burden in Huntington's disease: Pathology, phenotype, and mechanisms of compensation

  2014cites this paper
• Disruption of response inhibition circuits in prodromal Huntington disease.

  2014cites this paper
• A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington’s disease

  2014cites this paper
• Attempted and Successful Compensation in Preclinical and Early Manifest Neurodegeneration – A Review of Task fMRI Studies

  2014cites this paper
• Clinical and Biomarker Changes in Premanifest Huntington Disease Show Trial Feasibility: A Decade of the PREDICT-HD Study

  2014cites this paper
• Huntingtin Nuclear Localization: Current Insights into Mechanism and Regulation

  2013cites this paper
• Do cognitive problems start before motor dysfunction in animal models for Huntington Disease

  2013cites this paper
• A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases.

  2013cites this paper
• The Effect of Interference on Temporal Order Memory in Premanifest and Manifest Huntington's Disease

  2013cites this paper
• Cognitive decline in prodromal Huntington Disease: implications for clinical trials

  2013cites this paper
• Regional Atrophy Associated with Cognitive and Motor Function in Prodromal Huntington Disease

  2013cites this paper
• Treatment options for Huntington's disease

  2013cites this paper
• Pursuit of cognitive biomarkers: Longitudinal neuropsychological evaluation of pre-symptomatic Huntington's Disease

  2013cites this paper
• Transcranial magnetic stimulation as a tool for understanding neurophysiology in Huntington's disease: a review.

  2013cites this paper
• Seeking huntington disease biomarkers by multimodal, cross‐sectional basal ganglia imaging

  2013cites this paper
• eview ranscranial magnetic stimulation as a tool for understanding neurophysiology n Huntington ’ s disease : A review pril

  2013cites this paper
• Treatment options in Huntington's disease

  2013cites this paper
• Study of novel pathogenic mechanisms in Huntington disease

  2013cites this paper
• Cognition in Huntington's Disease in Manifest, Premanifest and Converting Gene Carriers Over Ten Years

  2013cites this paper
• Choosing an animal model for the study of Huntington's disease

  2013cites this paper
• Reliability and Minimal Detectable Change of Physical Performance Measures in Individuals With Pre-manifest and Manifest Huntington Disease

  2013cites this paper
• Cognitive Reserve and Brain Reserve in Prodromal Huntington's Disease

  2013cites this paper
• Changes of peripheral TGF-β1 depend on monocytes-derived macrophages in Huntington disease

  2013cites this paper
• Cognitive Dysfunction in Huntington's Disease: Humans, Mouse Models and Molecular Mechanisms

  2012cites this paper
• Biochemical Markers as Evidence of the Effects of Environmental Enrichment on Physiological Processes in Huntington’s Disease Patients

  2012cites this paper
• Operant-based instrumental learning for analysis of genetically modified models of Huntington's disease.

  2012cites this paper
• Development of the Huntington Disease Work Function Scale

  2012cites this paper
• Huntington Disease and Other Genetic Choreas

  2012cites this paper
• Cognitive domains that predict time to diagnosis in prodromal Huntington disease

  2012cites this paper
• Self Reports of Day-to-Day Function in a Small Cohort of People with Prodromal and Early HD

  2011cites this paper
• Role of the MID1/α4 protein complex in Huntington’s disease

  2011cites this paper
• Interneuron Cell Loss in the Human Cerebral Cortex in Huntington’s Disease

  2011cites this paper
• Cognitive Impairment in Huntington Disease: Diagnosis and Treatment

  2011cites this paper
• Role of manganese in neurodegenerative diseases.

  2011cites this paper
• Longitudinal functional magnetic resonance imaging of cognition in preclinical Huntington's disease.

  2011cites this paper
• Posttraumatic growth in Huntington disease: measuring the effects of genetic testing and disease on positive psychological change

  2011cites this paper